Genentech Inc.
Division of Roche
www.gene.com
Latest From Genentech Inc.
Oxurion's Anti-PIGF Antibody Disappoints in Diabetic Macular Edema
The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.
Advances On the Biosimilar Litigation Battlefield
A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gastrointestinal
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Ophthalmic
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Roche
- Senior Management
-
Alexander Hardy, CEO
Ed Harrington, CFO
Levi J Garraway, CMO & Head, Global Product Dev. - Contact Info
-
Genentech Inc.
Phone: (650) 225-1000
1 DNA Way
S. San Francisco, CA 94080
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice